V5 Ultimate
Compliance

PDG harmonisation (USP/EP/JP)

TL;DR

The Pharmacopoeial Discussion Group (PDG, USP+EP+JP, with USP-NF expansion to include Indian Pharmacopoeia from 2024) harmonises monographs and general chapters so a single test protocol can satisfy three pharmacopoeias. For supplements this matters most on excipients (microcr...

The Pharmacopoeial Discussion Group (PDG, USP+EP+JP, with USP-NF expansion to include Indian Pharmacopoeia from 2024) harmonises monographs and general chapters so a single test protocol can satisfy three pharmacopoeias. For supplements this matters most on excipients (microcrystalline cellulose, magnesium stearate, gelatin) and microbial chapters (USP <61>/<62> ↔ EP 2.6.12/2.6.13 ↔ JP 4.05) — a non-harmonised lot risks failing one market while passing another.

Regulatory anchors
  • USP General Notices
  • EP 5.8
  • JP General Information
How V5 handles it
QMS — quality engineered into every action, not bolted on.
Because V5 owns the operator action, the QMS sees the data the second it’s captured — not at the end of the shift.
Document control with hard kiosk-level training enforcement.
Versioned SOPs are only useful if operators are actually trained on the current version. V5 enforces it at the kiosk.
Related terms
USP <2021>/<2022>/<2023> microbial limits
Want to see PDG harmonisation (USP/EP/JP) in V5?

Free trial, no credit card, onboard in days, not months.

Start freeBook a demo
Back to glossary